| 1 |
21726410 | Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. | 2011 Dec |
9 |
| 2 |
19422321 | Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? | 2009 Jun |
2 |
| 3 |
16740353 | On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. | 2006 Oct |
3 |
| 4 |
17022718 | [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs]. | 2006 Jul-Aug |
1 |
| 5 |
15606435 | Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. | 2005 Jan |
6 |
| 6 |
15764711 | Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. | 2005 Jun |
6 |
| 7 |
16118328 | Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | 2005 Nov |
1 |
| 8 |
16308280 | Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. | 2005 Sep |
1 |
| 9 |
16342679 | [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. | 2005 Sep |
6 |
| 10 |
14709614 | Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation. | 2004 Jan |
12 |
| 11 |
15226678 | Identification of a novel variant CYP2C9 allele in Chinese. | 2004 Jul |
1 |
| 12 |
10640513 | Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. | 2000 Feb |
1 |
| 13 |
8857077 | Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. | 1996 |
8 |